Year None202420232022202120202019 Nov 13, 2024 Arcutis’ ZORYVE® (roflumilast) Awarded Best Eczema Treatment by Glamour Nov 06, 2024 Arcutis Announces Third Quarter 2024 Financial Results and Provides Business Update Nov 04, 2024 Arcutis Biotherapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) Oct 24, 2024 Arcutis Presents Positive Patient-Reported Outcome Data for ZORYVE® (Roflumilast) Cream 0.15% in Ato Oct 23, 2024 Arcutis to Report Third Quarter 2024 Financial Results and Participate in an Upcoming Investor Confe Oct 18, 2024 Arcutis Announces Health Canada Approval of ZORYVE® (Roflumilast) Foam 0.3% to Treat Seborrheic Derm Oct 04, 2024 Arcutis Biotherapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) Sep 25, 2024 New Data Shows ZORYVE® (Roflumilast) Cream 0.15% Provided Consistent Improvement of Atopic Dermatiti Sep 24, 2024 FDA Accepts Arcutis’ Supplemental New Drug Application for ZORYVE® (roflumilast) Foam for the Treatm Current page 1 Page 2 Page 3 Page 4 Page 5 Page 6 Next page next › Last page last » Displaying 1 - 9 of 53
